| Previous Close | 23.18 |
| Open | 23.30 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 22.79 - 23.30 |
| 52 Week Range | 12.59 - 29.80 |
| Volume | 201,020 |
| Avg. Volume | 427,695 |
| Market Cap | 890.62M |
| Beta (3Y Monthly) | 1.67 |
| PE Ratio (TTM) | 23.04 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it will be presenting at the Wells Fargo Securities 2019 Healthcare Conference on Thursday, September 5 at the Westin Copley Place in Boston.
NORTH BILLERICA, Mass.-- -- Worldwide revenue of $85.7 million for the second quarter 2019, representing an increase of 0.2% over the prior year period; mix of strong DEFINITY ® performance and TechneLite ® supply challenges Net income of $6.4 million for the second quarter 2019, representing a decrease of 34.2% from the prior year period GAAP diluted EPS of $0.16 for the second quarter 2019, representing ...
Lantheus Holdings, Inc. (the “Company”) (LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 25, 2019, to discuss its financial and operating results for the second quarter of 2019. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 7155758. A live audio webcast of the call will also be available in the Investors section of the Company’s website at www.lantheus.com.
Findings Show Improved Clinical Management and Decreased Length of Stay in Intensive Care Unit Patients Receiving DEFINITY-Enhanced Echocardiography Versus Non-Contrast Echocardiog
Company will also host a scientific symposium and interactive panel discussion focused on enhanced echocardiography
Lantheus expands into immuno-oncology and pharmaceutical services business through the license of NanoMab’s NM-01, an anti-PD-L1 imaging biomarker, designed to evaluate tumor immun
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Mary Anne Heino, President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m.
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Mary Anne Heino, President and Chief Executive Officer, and Robert Marshall, Chief Financial Officer, will present at the 2019 UBS Global Healthcare Conference at 1:00 p.m.
NORTH BILLERICA, Mass.-- -- Worldwide revenues of $86.5 million for the first quarter 2019, representing an increase of 4.7% over the prior year period Net income of $9.9 million for the first quarter 2019, representing an increase of 21.2% over the prior year period GAAP diluted EPS of $0.25 for the first quarter 2019, representing an increase of 20.3% over the prior year period; adjusted diluted ...
Lantheus Holdings, Inc. (the “Company”) (LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, April 30, 2019, to discuss its financial and operating results for the first quarter of 2019. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 8250839. A live audio webcast of the call will also be available in the Investors section of the Company’s website at www.lantheus.com.
NEW YORK , April 3, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Lantheus Holdings, Inc. (the “Company”) (LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with Cerevast Medical, Inc. (“Cerevast”) for the treatment of retinal vein occlusion (RVO), one of the most common causes of vision loss worldwide. This collaboration fits squarely into Lantheus’ growth strategy to identify new applications for its microbubble franchise and expand into new disease areas, such as ocular diseases. Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye.
Lantheus Holdings, Inc. (the “Company”) (LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Cesare Orlandi, M.D., Chief Medical Officer, will retire from the Company on September 2, 2019. In addition, John Bolla, the Company’s Senior Vice President, Technical Operations, has been promoted to the newly created position of Chief Operations Officer, effective immediately.
NORTH BILLERICA, Mass.-- -- Worldwide revenues of $86.3 million and $343.4 million for fourth quarter and full year 2018, respectively; representing an increase of 6.2% and 3.6% over the prior year period, respectively Net income of $13.3 million and $40.5 million for the fourth quarter and full year 2018, representing a decrease of $83.8 million and $82.9 million over the prior period, respectively, ...
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Lantheus Holdings, Inc. (the “Company”) (LNTH) announced today that it will release its financial results for the fourth quarter and full year of 2018 on Tuesday, February 19, 2019, after the market close. The Company will also provide financial guidance for 2019. The Company will host a conference call on Wednesday, February 20, 2019, at 8:00 a.m. ET to discuss its financial and operating results.
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 3:00 p.m.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercial
NORTH BILLERICA, Mass.-- -- Worldwide revenues of $88.9 million for the third quarter, an increase of 11.2% over the prior year period Net income for the third quarter of $9.3 million, or $0.24 per diluted share, an increase of 8.7% over the prior year period EBITDA of $20.0 million and Adjusted EBITDA of $26.1 million for the third quarter, an increase of 17.9% and 15.5% over the prior year period, ...
Lantheus Holdings, Inc. today announced that it will host a conference call at 4:30 p.m. ET on Tuesday, October 30, 2018, to discuss its financial and operating results for the third quarter of 2018.
Lantheus Holdings, Inc. , the parent company of Lantheus Medical Imaging, Inc. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, and Robert Marshall, Chief Financial Officer and Treasurer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference ...